NuVasive (NUVA) and Halyard Health (HYH) Financial Contrast

NuVasive (NASDAQ: NUVA) and Halyard Health (NYSE:HYH) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Volatility & Risk

NuVasive has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Halyard Health has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.

Profitability

This table compares NuVasive and Halyard Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NuVasive 3.50% 13.04% 5.81%
Halyard Health 3.06% 8.29% 4.44%

Institutional and Insider Ownership

91.0% of Halyard Health shares are held by institutional investors. 1.2% of NuVasive shares are held by company insiders. Comparatively, 1.3% of Halyard Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares NuVasive and Halyard Health’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
NuVasive $1.02 billion 3.06 $225.78 million $0.62 99.03
Halyard Health $1.60 billion 1.34 $182.00 million $1.03 44.50

NuVasive has higher revenue, but lower earnings than Halyard Health. Halyard Health is trading at a lower price-to-earnings ratio than NuVasive, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for NuVasive and Halyard Health, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NuVasive 1 2 10 0 2.69
Halyard Health 0 1 3 0 2.75

NuVasive currently has a consensus target price of $80.27, suggesting a potential upside of 30.74%. Halyard Health has a consensus target price of $41.67, suggesting a potential downside of 9.08%. Given NuVasive’s higher probable upside, analysts clearly believe NuVasive is more favorable than Halyard Health.

Summary

NuVasive beats Halyard Health on 8 of the 14 factors compared between the two stocks.

About NuVasive

Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

About Halyard Health

Halyard Health, Inc. is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections. The Company address healthcare needs, such as reducing the use of opioids, while helping patients move from surgery to recovery. The Medical Devices segment’s products include post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems and enteral feeding tubes. The S&IP segment includes product offerings, such as sterilization wrap, surgical drapes and gowns, facial protection, protective apparel and medical exam gloves.

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply